Resumen

RASCON-MARTINEZ, Dulce M; MENDOZA-PINEDA, Lloaly  y  CARRILLO-TORRES, Orlando. Beyond tissue damage: nociplastic diseases and the emerging role of ketamine. Rev. mex. anestesiol. [online]. 2025, vol.48, n.4, pp.229-235.  Epub 30-Ene-2026. ISSN 0484-7903.  https://doi.org/10.35366/121398.

Nociplastic diseases are conditions characterized by the presence of persistent chronic pain despite the absence of clear evidence of actual or potential tissue damage that would trigger the activation of peripheral nociceptors, or evidence of disease or injury to the somatosensory system. This process of nociplasticity potentially leads to a state of heightened pain sensitivity or, alternatively, allodynia. It is estimated that approximately two-thirds of painful musculoskeletal disorders may be categorized within this class. These conditions pose challenges for healthcare professionals, as conventional therapies aimed at pain management often prove inadequate, and their presence marks a significant transformation in the perception and approach to chronic pain within the medical domain. A non-systematic review was conducted to understand the characteristics of ketamine for analgesia in various nociplastic diseases. This article aims to provide a descriptive review of the current literature on the role of ketamine in the treatment of chronic pain associated with nociplastic diseases. Additionally, the challenges and opportunities inherent in its application in the clinical context will be examined. The PICO methodology (P: population, I: intervention, C: comparison, and O: outcome) was employed for constructing the research question and conducting the literature search, where the population consisted of patients with nociplastic diseases, the intervention was the use of ketamine, no drugs or interventions were sought for comparison, and the outcomes were the efficacy in reducing nociplastic pain.

Palabras llave : pain; nociplastic pain; ketamine.

        · resumen en Español     · texto en Español     · Español ( pdf )